Burgess Justin 4
4 · DYNAVAX TECHNOLOGIES CORP · Filed Mar 4, 2024
Insider Transaction Report
Form 4
Burgess Justin
VP Finance & CAO
Transactions
- Exercise/Conversion
Stock Options (Right to Buy)
2024-03-01−4,334→ 8,666 totalExercise: $11.12Exp: 2030-02-15→ Common Stock (0 underlying) - Exercise/Conversion
Common Stock
2024-03-01$11.12/sh+4,334$48,194→ 17,759 total - Exercise/Conversion
Common Stock
2024-03-01$9.41/sh+2,767$26,037→ 20,526 total - Sale
Common Stock
2024-03-01$12.78/sh−7,101$90,751→ 13,425 total - Sale
Common Stock
2024-03-01$12.78/sh−13,425$171,572→ 0 total - Exercise/Conversion
StockOptions (Right to Buy)
2024-03-01−2,767→ 0 totalExercise: $9.41Exp: 2028-02-02→ Common Stock (0 underlying)
Footnotes (5)
- [F1]Code M - Exercise or conversion of derivative security
- [F2]Code S - Open market or private sale of non-derivative or derivative security
- [F3]This transaction was executed in multiple trades at prices ranging from $12.73 to $12.81; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
- [F4]This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 16, 2023, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.
- [F5]This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 3, 2021, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.